Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 19:25:32 01/06/2026 +03			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 88.58K 81.71K 75.46K 143K 9.66M 146K 976K 383K 4.76M 380K 372K 16.36M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.91M 9.14M 8.45M 16.02M 1.08B 16.29M 109M 42.9M 532M 42.55M 41.63M 1.83B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/10/25	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/08/25	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/05/25	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/04/25	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/11/24	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
18/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/10/24	Top Midday Decliners	MT
15/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
27/09/24	Top Midday Decliners	MT
24/09/24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24/09/24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/09/23	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/09/23	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/09/23	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/05/23	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/03/23	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise

22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	01/01/2019
Michael Golembiewski DFI	Director of Finance/CFO	54	01/09/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/02/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
12/01/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%
12/01/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	-	-100.00%	136
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+59.82%	+92.96%	54.88B
ARGENX SE	-4.14%	-8.06%	+58.96%	+118.67%	54.63B
INSMED INCORPORATED	-2.24%	+3.59%	+17.75%	+477.47%	25.06B
BIONTECH SE	-1.60%	-6.21%	-18.96%	-15.21%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+42.44%	-1.27%	19.87B
GENMAB A/S	-3.19%	0.00%	+35.60%	-26.98%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	16.5B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+51.91%	+726.40%	15.75B
EXELIXIS, INC.	-1.05%	+1.16%	+25.95%	+194.27%	14.2B
Average	+989.40%	-0.25%	+52.07%	+182.35%	24.16B
Weighted average by Cap.	-0.89%	-1.45%	+51.26%	+177.14%

	2022	2023
Net sales	-	2.2 1.93 1.78 1.64 3.11 210.11 3.17 21.24 8.34 103.51 8.27 8.09 355.83
Net income	-73.53M -64.32M -59.33M -54.79M -104M -7.01B -106M -709M -278M -3.45B -276M -270M -11.88B	-37.88M -33.14M -30.56M -28.23M -53.56M -3.61B -54.46M -365M -143M -1.78B -142M -139M -6.12B
Net Debt	4.59M 4.01M 3.7M 3.42M 6.49M 438M 6.6M 44.24M 17.37M 216M 17.23M 16.86M 741M	11.23M 9.82M 9.06M 8.37M 15.88M 1.07B 16.15M 108M 42.52M 528M 42.17M 41.26M 1.81B